Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.86 |
| ▸ | USP2 | O75604 | 5/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.86 |
| ▸ | DRD2 | P14416 | 5/20 | 0.86 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.86 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.86 |
| ▸ | DRD1 | P21728 | 5/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergocristine SCHEMBL4947691 | 1.00 | CYP2C9 (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL30957132 | 1.00 | CYP2C9 (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL455906 | 1.00 | CYP2C9 (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL14029486 | 1.00 | CYP2C9 (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL20136277 | 0.98 | CYP2C9 (0.96) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL11081603 | 0.98 | CYP2C9 (0.96) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL18208064 | 0.98 | CYP2C9 (0.96) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocristine SCHEMBL29386896 | 0.94 | MAPT (0.89) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocryptine SCHEMBL78951 | 0.92 | KDM4E (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 | |
| Ergocryptine SCHEMBL11034170 | 0.92 | KDM4E (1.00) | CYP2C9MAPTMEN1KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4620936-A1 | PROCESS FOR THE PREPARATION OF N6-ISOTOPE-LABELED ERGOT ALKALOIDS, IN PARTICULAR LYSERGIC ACID AMIDES AND ERGOPEPTINES | Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Klimaschutz, dieser vertreten durch den Präsidenten der (DE) | 2025-09-24 | — | — | EP | claimed |
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| EP-4220161-A1 | A BUFFER SYSTEM FOR PARTICLE-BASED MULTIPLEXED IMMUNOASSAYS | Bundesrepublik Deutschland, vertreten durch den Bundesminister für Wirtschaft und Energie (DE) | 2023-08-02 | — | — | EP | claimed |
| US-20200222386-A1 | AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE | KYOTO UNIVERSITY (JP) | 2020-07-16 | — | — | US | claimed |
| EP-3646872-A1 | AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE | Kyoto University (JP) | 2020-05-06 | — | — | EP | claimed |
| WO-2002089798-A2 | METHOD AND COMPOSITIONS FOR TREATING MIGRAINES | MERCK & CO., INC. (US) | 2002-11-14 | — | — | WO | claimed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | claimed |
| EP-1018879-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED INC (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2002024865-A2 | MODULATION OF SECONDARY METABOLITE PRODUCTION BY ZINC BINUCLEAR CLUSTER PROTEINS | MICROBIA, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1018879-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | Nitromed, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1997027749-A1 | NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED, INC. (US) | 1997-08-07 | — | — | WO | claimed |
| US-5573776-A | Oral osmotic device with hydrogel driving member | ALZA CORPORATION (US) | 1996-11-12 | — | — | US | claimed |
| US-5468486-A | Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1995-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | CYP2C9 3224/4885MAPT 3308/4885MEN1 1/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | CYP2C9 583/4885MAPT 126/4885MEN1 3390/4885 |
| US-20200222386-A1 | AGENT FOR PREVENTING AND/OR TREATING ALZHEIMER'S DISEASE | PSEN1, APP, PSEN2 | CYP2C9 4620/4885MAPT 6/4885MEN1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.